

Cristiano Caruso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1259685/publications.pdf>

Version: 2024-02-01

80
papers

2,380
citations

201674

27
h-index

233421

45
g-index

81
all docs

81
docs citations

81
times ranked

2788
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149. | 2.2 | 19 |
| 2 | Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. <i>Dermatology</i> , 2022, 238, 717-724. | 2.1 | 8 |
| 3 | EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1667-1684. | 5.7 | 12 |
| 4 | Detection Of Serum Specific IgE By Fluoro-Enzyme Immunoassay For The Diagnosis Of Immediate Allergic Reactions To Penicillins. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, AB80. | 2.9 | 0 |
| 5 | Characterization of Italian severe uncontrolled Asthmatic patients Key features when receiving Benralizumab in a real-life setting: the observational retrospective ANANKE study. <i>Respiratory Research</i> , 2022, 23, 36. | 3.6 | 14 |
| 6 | Heterogeneous Condition of Asthmatic Children Patients: A Narrative Review. <i>Children</i> , 2022, 9, 332. | 1.5 | 2 |
| 7 | Nasal Cytology: A Easy Diagnostic Tool in Precision Medicine for Inflammation in Epithelial Barrier Damage in the Nose. A Perspective Mini Review. <i>Frontiers in Allergy</i> , 2022, 3, . | 2.8 | 7 |
| 8 | Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. <i>Frontiers in Allergy</i> , 2022, 3, . | 2.8 | 9 |
| 9 | Detection of Serum-Specific IgE by Fluoro-Enzyme Immunoassay for Diagnosing Type I Hypersensitivity Reactions to Penicillins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6992. | 4.1 | 8 |
| 10 | Evaluating Immediate Reactions to Cephalosporins: Time Is of the Essence. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1648-1657.e1. | 3.8 | 13 |
| 11 | Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 37-43. | 2.6 | 62 |
| 12 | Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1569-1571. | 5.7 | 6 |
| 13 | Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1830-1837.e15. | 2.9 | 26 |
| 14 | Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509. | 3.5 | 14 |
| 15 | Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274. | 10.7 | 102 |
| 16 | Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1057-1060. | 2.5 | 7 |
| 17 | Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2776-2784. | 5.7 | 19 |
| 18 | Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755. | 1.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review. <i>Metabolites</i> , 2021, 11, 647. | 2.9 | 5 |
| 20 | β-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 31-46. | 3.4 | 20 |
| 21 | Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. <i>Clinical and Translational Allergy</i> , 2021, 11, e12067. | 3.2 | 7 |
| 22 | Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606. | 3.5 | 18 |
| 23 | The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1460-1463. | 5.7 | 16 |
| 24 | Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. <i>Internal Medicine Journal</i> , 2020, 50, 1483-1491. | 0.8 | 19 |
| 25 | Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903. | 3.7 | 9 |
| 26 | Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464. | 3.5 | 30 |
| 27 | Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3640-3642. | 3.8 | 9 |
| 28 | Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328. | 3.3 | 36 |
| 29 | COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233. | 0.9 | 40 |
| 30 | Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1283-1286. | 1.8 | 4 |
| 31 | Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. <i>BioMed Research International</i> , 2020, 2020, 1-4. | 1.9 | 5 |
| 32 | Tolerability of Cefazolin and Ceftibuten in Patients with IgE-Mediated Aminopenicillin Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1989-1993.e2. | 3.8 | 23 |
| 33 | Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2358-2363. | 3.8 | 96 |
| 34 | Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. <i>Respiratory Medicine</i> , 2020, 171, 106080. | 2.9 | 28 |
| 35 | Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068. | 3.7 | 76 |
| 36 | Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 201-204. | 1.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2653-2661. | 5.7 | 20 |
| 38 | Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 27. | 2.0 | 11 |
| 39 | Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. <i>Respiratory Medicine</i> , 2020, 166, 105947. | 2.9 | 55 |
| 40 | Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163. | 6.7 | 56 |
| 41 | Modulation of gut microbiota in patients with IBS and systemic nickel allergy after diet and probiotic supplementation: a pilot study. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2020, 34, 1929-1934. | 0.7 | 1 |
| 42 | Real-life studies of biologics used in asthma patients: key differences and similarities to trials. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 951-958. | 3.0 | 20 |
| 43 | One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836. | 2.6 | 57 |
| 44 | Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2539-2541. | 5.7 | 36 |
| 45 | Acquired cow's milk sensitization after liver transplant in an adult: clinical implications and future strategies. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 11. | 2.0 | 0 |
| 46 | Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 87-89. | 2.6 | 15 |
| 47 | One year of mepolizumab in severe asthma in Italy: efficacy and safety. , 2019, , . | | 0 |
| 48 | Switch Omalizumab to Mepolizumab: real life experience. , 2019, , . | | 0 |
| 49 | Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1662-1672. | 3.8 | 111 |
| 50 | Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic granulomatosis with polyangiitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 209-211. | 1.0 | 3 |
| 51 | Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. <i>World Allergy Organization Journal</i> , 2018, 11, 33. | 3.5 | 25 |
| 52 | Nasal cytology: Methodology with application to clinical practice and research. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1092-1106. | 2.9 | 47 |
| 53 | Safety of an Accelerated Build-up Phase With Pollen Allergoids: A Retrospective Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 283-284. | 1.3 | 2 |
| 54 | Aspirin challenge and desensitization: how, when and why. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 247-254. | 2.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 23. | 5.3 | 25 |
| 56 | Diagnosing Î²-Lactam Hypersensitivity. <i>Current Pharmaceutical Design</i> , 2017, 22, 6803-6813. | 1.9 | 1 |
| 57 | Patientsâ€™ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting. , 2017, , . | | 0 |
| 58 | Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1533-1539. | 5.7 | 51 |
| 59 | Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 179-186. | 2.9 | 64 |
| 60 | Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 331-332. | 2.9 | 1 |
| 61 | Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1428. | 2.9 | 3 |
| 62 | Allergenic significance of cephalosporin side chains. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1426-1428. | 2.9 | 9 |
| 63 | IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 685-691.e3. | 2.9 | 126 |
| 64 | Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 972-976. | 2.9 | 75 |
| 65 | Natural evolution of skin test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 806-809. | 5.7 | 72 |
| 66 | A Survey of Clinical Features of Allergic Rhinitis in Adults. <i>Medical Science Monitor</i> , 2014, 20, 2151-2156. | 1.1 | 12 |
| 67 | Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1618-1621. | 5.7 | 42 |
| 68 | Lipid transfer proteins: the most frequent sensitizer in Italian subjects with food-dependent exercise-induced anaphylaxis. <i>Clinical and Experimental Allergy</i> , 2012, 42, 1643-1653. | 2.9 | 110 |
| 69 | Diagnosing nonimmediate reactions to cephalosporins. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1166-1169. | 2.9 | 82 |
| 70 | Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. <i>Clinical and Experimental Allergy</i> , 2011, 41, 96-103. | 2.9 | 48 |
| 71 | Omalizumab efficacy in a girl with atopic eczema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 278-279. | 5.7 | 18 |
| 72 | The very limited usefulness of skin testing with penicilloyl-polylysine and the minor determinant mixture in evaluating nonimmediate reactions to penicillins. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1104-1107. | 5.7 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 994-999. | 2.9 | 138 |
| 74 | Delayed hypersensitivity to bosentan. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 499-501. | 5.7 | 8 |
| 75 | Same-patient allergy to ampicillin and human insulin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1105-1107. | 5.7 | 3 |
| 76 | Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs. <i>Current Pharmaceutical Design</i> , 2008, 14, 2826-2832. | 1.9 | 16 |
| 77 | Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. <i>International Archives of Allergy and Immunology</i> , 2007, 143, 103-108. | 2.1 | 23 |
| 78 | A comparison of the performance of two penicillin reagent kits in the diagnosis of <i>β</i> -lactam hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 53-58. | 5.7 | 52 |
| 79 | Cross-reactivity among drugs: clinical problems. <i>Toxicology</i> , 2005, 209, 169-179. | 4.2 | 46 |
| 80 | Celecoxib Tolerability in Patients with Hypersensitivity (Mainly Cutaneous Reactions) to Nonsteroidal Anti-Inflammatory Drugs. <i>International Archives of Allergy and Immunology</i> , 2005, 137, 145-150. | 2.1 | 23 |